GeNeuro: Funding, Investors & Team (Sep 2026)
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.
GeNeuro has raised $27.8M across 4 funding rounds on record, the most recent an undisclosed round of $5.4M announced in Feb 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
GeNeuro Company Profile and Key Stats
Latest funding round on record: Feb 2024.
GeNeuro Funding Rounds
GeNeuro raised $7.1M in a Post-IPO Equity announced in Jul 2021.
5 months later, a Grant of $7.2M was announced in Dec 2021.
5 months later, a Post-IPO Equity of $8.1M was announced in May 2022.
1.8 years later, an undisclosed round of $5.4M was announced in Feb 2024.
GeNeuro Founders and Leadership Team
No contact details are on record for this team yet.
GeNeuro Funding Compared to Other Biotechnology Startups
GeNeuro's latest round of $5.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like GeNeuro in Biotechnology and Geneva
Companies Similar to GeNeuro
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
GeNeuro Funding FAQs
What does GeNeuro do?
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.
How much funding has GeNeuro raised?
GeNeuro has raised $27.8M across 4 rounds on record. The most recent is an undisclosed round of $5.4M announced in Feb 2024.
When did GeNeuro last raise funding?
GeNeuro's most recent funding round on record is an undisclosed round of $5.4M, announced in Feb 2024.
Who founded GeNeuro?
FundedIQ lists Jesus Martin Garcia (Founder) at GeNeuro.
Who is the CEO of GeNeuro?
Jesus Martin-Garcia is listed as CEO at GeNeuro.
Where is GeNeuro headquartered?
GeNeuro is based in Geneva, Geneve, Switzerland.
How many employees does GeNeuro have?
GeNeuro is in the 11-50 employee band.
How does GeNeuro's funding compare to other Biotechnology startups?
GeNeuro's latest round of $5.4M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's GeNeuro Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GeNeuro is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.